Eloquest Healthcare launches next-generation urinary management system, the ReliaFit Male Urinary Device

Press Release

By:

Ref: PR Newswire

Published: 07/23/2013

Eloquest Healthcare launches next-generation urinary management system, the ReliaFit Male Urinary Device

- ReliaFit™ reduces the risk of catheter-associated urinary tract infections (CAUTIs), device leakage and healthcare-acquired skin injuries

FERNDALE, Mich., July 23, 2013 /PRNewswire/ -- Eloquest Healthcare today announced the launch of the ReliaFit™ Male Urinary Device, a next-generation external catheter that minimizes the risk of urinary tract infections often associated with indwelling catheters. The unique design of ReliaFit also provides a superior level of dryness and patient comfort.

(Logo:  http://photos.prnewswire.com/prnh/20130723/DE51604LOGO-a )

(Logo:  http://photos.prnewswire.com/prnh/20130723/DE51604LOGO-b )

"We are pleased to add ReliaFit to our specialized portfolio of easy-to-use products that improve patient outcomes and reduce treatment costs," states Tim O'Halla, Executive Vice President & COO. "ReliaFit will revolutionize urinary management by reducing infection rates and improving patient care and satisfaction."

The main challenges with current urinary management options are catheter-associated urinary tract infections (CAUTIs) that are common with indwelling catheters, and discomfort and leakage when using condom catheters.

Despite being the most frequently used catheterization tool in the acute care setting, Foley indwelling catheters contribute to a very prevalent type of hospital-acquired infections (HAIs), CAUTIs.1,2 These infections result in a significant increase in treatment costs, length of hospital stay and use of antimicrobials.2-6 Because of its noninvasive design, ReliaFit helps to reduce the risk of UTIs.7 In a pilot study of 42 applications of ReliaFit by 31 nurses in 20 acute-care patients, there were no CAUTIs reported.8

Although condom catheters reduce the risk of infection, they are not preferred by most healthcare professionals because of leakage and application challenges. Condom catheters often fail to stay in place because of incorrect sizing and placement, leading to urine spillage. ReliaFit is an easy-to-apply, one-size-fits-all alternative for most condom catheter patients. Unlike condom catheters, ReliaFit is appropriate for use in patients with retracted, circumcised and uncircumcised anatomies. The device features a comfortable hydrocolloid seal and faceplate which - along with a vent to improve drainage - reduces the risk of moisture-related skin breakdown.

ReliaFit is an alternative for many patients that results in improved quality of care and patient satisfaction.

About ReliaFit Male Urinary Device

ReliaFit is an external catheter for male urinary management. It features a gentle, hydrocolloid seal that conforms to the skin, a flexible faceplate that fits any size anatomy (including uncircumcised and retracted anatomy), and a vent to improve drainage. It also includes Mastisol®, a non-water soluble adhesive with a proven safety profile, to increase the securement of ReliaFit to the patient's anatomy. ReliaFit can be connected to most leg or bedside urine drainage bags. For additional securement and improved performance, a product set including the securement device CathGrip® is available. ReliaFit is manufactured through a partnership between Eloquest and Bioderm, Inc., who sells the product as Men's Liberty™ (www.mensliberty.com) in the non-acute care setting. 

About Catheter-Associated Urinary Tract Infections (CAUTIs)

HAIs are the fifth leading cause of death in hospitals and urinary tract infections make up about 40 percent of all HAIs.2,3,6 Of those, 80 percent of UTIs are attributable to indwelling urinary catheterization.2,3 In the U.S. alone, CAUTIs cost $424 to $451 million dollars per year.2 The increased cost includes longer hospital stays extended by an average of two to four days.3-5 In addition, the use of antimicrobials to treat CAUTIs may contribute to the development of antimicrobial resistance.6

About Eloquest Healthcare

Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale Pharma Group, Inc. that is focused specifically on serving hospitals, their healthcare practitioners, and patients. Eloquest Healthcare helps deliver safer, more compassionate care by providing intuitive, cost-effective solutions that complement treatment protocols. More information can be found at http://www.eloquesthealthcare.com

References

1. Catheters. RAK Associates Website. http:// www.rakassociates.com/docs/RAK051203CC_ Catheter_Example.pdf. Published December 2008. Accessed May 8, 2013.

2. Gray M. Reducing catheter-associated urinary tract infection in the critical care unit. AACN Advanced Critical Care. 2010;21(3):247-257.

3. Saint S. Clinical and economic consequences of nosocomial catheter-related bacteriuria. Am J Infect Control. 2000;28(1):68-75.

4. Givens CD, Wenzel RP. Catheter associated urinary tract infections in surgical patients: a controlled study on the excess morbidity and costs. J Urol. 1980;124(5):646-648.

5. Green MS, Rubinstein E, Amit P. Estimating the effects of nosocomial infections on the length of hospitalization. J Infect Dis. 1982;145(5):667-672.

6. Stone PW. Economic burden of healthcare associated infections: an American perspective. Expert Rev Pharmacoeconomics Outcomes Res. 2009;9(5):417-422.

7. Urinary Output Monitoring and Management in Acute Care: Clinical Pathway for CMS 1533 Compliance and Positive Economic Impact of Compliance (white paper). http://mensliberty.com/health-professionals-reduce-utiwith-mens-liberty/. Accessed May 16, 2013.

8. Lucas LM, Iseler J, Gale L. Evaluation of a new, novel male external urinary management device. Poster presented at: Cleveland Clinic's Spring 2013 WOC Nursing Symposium; April 12, 2013; Cleveland, OH.

SOURCE Eloquest Healthcare